First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial - Quiz - MDSpire

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial

  • By

  • Peter Schmid

  • Seock-Ah Im

  • Zbigniew Nowecki

  • Piotr J. Wysocki

  • Jacek Jassem

  • Kyung Hae Jung

  • Simon Lord

  • Jon Armstrong

  • Ross Stewart

  • Petra Vuković

  • Neelima Denduluri

  • Yeon Hee Park

  • June 8, 2026

  • 0 min

Share

Original Source(s)

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial

  • by Peter Schmid, Seock-Ah Im, Zbigniew Nowecki, Piotr J. Wysocki, Jacek Jassem, Kyung Hae Jung, Simon Lord, Jon Armstrong, Ross Stewart, Petra Vuković, Neelima Denduluri, Yeon Hee Park

  • June 8, 2026

Related Content

Multi-omics analysis of kidney renal cell carcinoma in silico with preliminary in vivo validation

Tagraxofusp in adult blastic plasmacytoid dendritic cell neoplasm: clinical trials and real-world outcomes: a systematic review

First-line serplulimab plus chemotherapy versus chemotherapy alone in small-cell lung cancer patients with brain metastases: a multicenter, prospective cohort study